465 assets in Obesity Disorder

Therapeutic assets addressing Obesity Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pegloxenatide Obesity Disorder	Fudan University	P2/3	CCC (50)
pf-07976016 Obesity Disorder	Pfizer	P2	CCC (50)
ro7795081 Obesity Disorder	Hoffmann-La Roche	P2	CCC (50)
Synthetic Levothyroxine Obesity Disorder	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	P3	CCC (50)
Tenofovir Alafenamide Obesity Disorder	José Antonio Mata Marín	P3	CCC (50)
Thdbh120 Obesity Disorder	Tonghua Dongbao Pharmaceutical Co.,Ltd	P2	CCC (50)
Vrb-101 Obesity Disorder	Verdiva Bio Dev Limited	P2	CCC (50)
Zenagamtide Obesity Disorder	Novo Nordisk A/S	P3	CCC (50)
Ard-101 Obesity Disorder	Aardvark Therapeutics, Inc.	P2	CCC (49)
Bimagrumab Obesity Disorder	Massachusetts General Hospital	P2	CCC (48)
Ecnoglutide Obesity Disorder	Hangzhou Sciwind Biosciences Co., Ltd.	P1/2	CCC (48)
Enobosarm Obesity Disorder	Veru Inc.	P2	CCC (48)
Gly-200 Obesity Disorder	Glyscend, Inc.	P2	CCC (48)
Gsbr-1290 Obesity Disorder	Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics	P1/2	CCC (48)
Inv-202 Obesity Disorder	Inversago Pharma Inc.	P2	CCC (48)
kds2010 Obesity Disorder	NeuroBiogen Co., Ltd	P2	CCC (48)
Mibavademab Obesity Disorder	Eli Lilly and Company	P2	CCC (48)
Nbt-Nm108 Obesity Disorder	Rutgers, The State University of New Jersey	P2	CCC (48)
Nicotine Obesity Disorder	Brown University	P2	CCC (48)
nnc0662-0419 Obesity Disorder	Novo Nordisk A/S	P2	CCC (48)
Oat Kernel Meal Obesity Disorder	University of Toronto	P2	CCC (48)
pf-08653945 Obesity Disorder	Pfizer	P2	CCC (48)
Pyy(3-36) Obesity Disorder	University College, London	P2	CCC (48)
Sacubitril Obesity Disorder	University of Alabama at Birmingham	P2/3	CCC (48)
TE-8105 Obesity Disorder	Immunwork, Inc.	P1/2	CCC (48)
Vigabatrin Obesity Disorder	Washington University School of Medicine	P2	CCC (48)
vtx3232 Obesity Disorder	Zomagen Biosciences Ltd.	P2	CCC (48)
Cissus Quadrangularia Obesity Disorder	University of Yaounde 1	P1/2	CC (47)
Dasatinib Obesity Disorder	Cedars-Sinai Medical Center	P2/3	CC (47)
dr10624 for Obesity Disorder	Zhejiang Doer Biologics Co., Ltd.	P1	CC (47)
rn3161 Obesity Disorder	Ikaria Bioscience Pty Ltd	P1/2	CC (47)
Umbilical Cord Mesenchymal Stem Cell Obesity Disorder	Nguyen Ton Ngoc Huynh	P1/2	CC (47)
Wve-007 Obesity Disorder	Wave Life Sciences USA, Inc.	P1/2	CC (47)
10-NITRO-OLEIC ACID Obesity Disorder	University of Colorado, Denver	P2	CC (46)
[6,6-2H2] D-glucose Obesity Disorder	Columbia University	P1	CC (46)
Akk Obesity Disorder	Central South University	P2	CC (46)
Azelaprag Obesity Disorder	BioAge Labs, Inc.	P2	CC (46)
Bicarbonate Ion Obesity Disorder	Eli Lilly and Company	P1	CC (46)
Bis-Octanoyl -1,3-Butanediol Obesity Disorder	Washington University School of Medicine	P2	CC (46)
Bremelanotide Obesity Disorder	Palatin Technologies, Inc	P2	CC (46)
cs060380 Obesity Disorder	Cascade Pharmaceuticals, Inc	P2	CC (46)
Disulfiram Obesity Disorder	University of Oklahoma	P2	CC (46)
Epigallocatechin-3-Gallate Obesity Disorder	Purdue University	P2	CC (46)
Glycerin,Anhydrous Obesity Disorder	Rutgers, The State University of New Jersey	P2	CC (46)
ht-6184 Obesity Disorder	Halia Therapeutics, Inc.	P2	CC (46)
Kbp-336 Obesity Disorder	KeyBioscience AG	P2	CC (46)
L-Ctirulline Obesity Disorder	University of Colorado, Denver	P2	CC (46)
ly6249492 Obesity Disorder	Eli Lilly and Company	P2	CC (46)
mbl949 Obesity Disorder	Novartis Pharmaceuticals	P2	CC (46)
mkp10241 Obesity Disorder	Mankind Pharma Limited	P2	CC (46)

Showing 201 to 250 of 465 assets

PreviousPage 5 of 10Next